Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842086 | 0.82 | IDO1 (0.42) | ALDH1A1RAB9ASMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL2123730 | 0.82 | ALDH1A1 (0.47) | ALDH1A1RAB9ASMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL2123079 | 0.79 | CNR2 (0.44) | ALDH1A1L3MBTL1KDM4ENPSR1MAPT | |
| SCHEMBL2123728 | 0.77 | NPC1 (0.42) | METAP2ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL2122470 | 0.73 | IDO1 (0.42) | ALDH1A1RAB9ASMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL731127 | 0.72 | ALDH1A1 (0.47) | METAP2ALDH1A1SMN1; SMN2HSD17B10HSP90AA1 | |
| SCHEMBL2124969 | 0.71 | METAP2 (0.49) | METAP2ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL29840676 | 0.71 | METAP2 (0.49) | METAP2ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3629826 | 0.70 | ALDH1A1 (0.57) | METAP2ALDH1A1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL29788337 | 0.70 | CA1 (0.71) | METAP2ALDH1A1RAB9ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | claimed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | claimed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | claimed |
| EP-1456182-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | AstraZeneca AB (SE) | 2004-09-15 | — | — | EP | claimed |
| WO-2003048133-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| US-20120095011-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20090131463-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | disclosed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | disclosed |
| EP-1456182-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | AstraZeneca AB (SE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003048133-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131463-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | METAP2 4480/4885ALDH1A1 1142/4885RAB9A 618/4885 |
| US-20120095011-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | METAP2 4480/4885ALDH1A1 1142/4885RAB9A 618/4885 |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | IGF1R, IGFBP1, INSR | METAP2 3627/4885ALDH1A1 1133/4885RAB9A 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.